These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11115721)

  • 21. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
    Joseph A; Louria-Hayon I; Plis-Finarov A; Zeira E; Zakay-Rones Z; Raz E; Hayashi T; Takabayashi K; Barenholz Y; Kedar E
    Vaccine; 2002 Sep; 20(27-28):3342-54. PubMed ID: 12213404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.
    Weeratna RD; Brazolot Millan CL; McCluskie MJ; Siegrist CA; Davis HL
    FEMS Immunol Med Microbiol; 2001 Apr; 30(3):241-7. PubMed ID: 11335145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo.
    Zhang L; Tian X; Zhou F
    Int Immunopharmacol; 2007 Dec; 7(13):1732-40. PubMed ID: 17996683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice.
    Chen Z; Cao J; Liao X; Ke J; Zhu S; Zhao P; Qi Z
    Viral Immunol; 2011 Jun; 24(3):199-209. PubMed ID: 21668361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunostimulatory DNA is a potent mucosal adjuvant.
    Horner AA; Ronaghy A; Cheng PM; Nguyen MD; Cho HJ; Broide D; Raz E
    Cell Immunol; 1998 Nov; 190(1):77-82. PubMed ID: 9826449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery.
    Bhat AA; Seth RK; Babu J; Biswas S; Rao DN
    Int Immunopharmacol; 2009 Sep; 9(10):1197-208. PubMed ID: 19595793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
    J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J; Adamsson J; Harandi AM
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
    Linghua Z; Xingshan T; Fengzhen Z
    Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice.
    Peng Z; Wang H; Mao X; HayGlass KT; Simons FE
    Int Immunol; 2001 Jan; 13(1):3-11. PubMed ID: 11133829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
    J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides.
    Zhou X; Zheng L; Liu L; Xiang L; Yuan Z
    Scand J Immunol; 2003 Sep; 58(3):350-7. PubMed ID: 12950682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase.
    Hochreiter R; Hartl A; Freund J; Valenta R; Ferreira F; Thalhamer J
    Int Arch Allergy Immunol; 2001; 124(1-3):406-10. PubMed ID: 11307030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.